BR112017019343A2 - uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas - Google Patents
uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmasInfo
- Publication number
- BR112017019343A2 BR112017019343A2 BR112017019343A BR112017019343A BR112017019343A2 BR 112017019343 A2 BR112017019343 A2 BR 112017019343A2 BR 112017019343 A BR112017019343 A BR 112017019343A BR 112017019343 A BR112017019343 A BR 112017019343A BR 112017019343 A2 BR112017019343 A2 BR 112017019343A2
- Authority
- BR
- Brazil
- Prior art keywords
- tumor
- lung cancer
- small cell
- reduce
- cell lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Abstract
a invenção descrita provê composições farmacêuticas, sistemas e métodos para tratar um tumor sólido de câncer de pulmão de células não pequenas (nsclc) compreendendo uma população de células tumorais. o método inclui a administração de uma composição farmacêutica compreendendo uma quantidade terapêutica de um polipeptídeo tendo a sequência de aminoácidos yaraaarqarakalarqlgvaa (seq id no: 1) ou seu equivalente funcional e um carreador farmaceuticamente aceitável, em que a quantidade terapêutica do polipeptídeo é eficaz para inibir uma atividade de cinase na população de células tumorais e reduzir a proliferação de células cancerígenas, reduzir o tamanho do tumor, reduzir a carga tumoral, induzir a morte de célula tumoral, superar a quimiorresistência tumoral, intensificar a quimiossensibilidade tumoral ou uma combinação destes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562132374P | 2015-03-12 | 2015-03-12 | |
PCT/US2016/021843 WO2016145234A2 (en) | 2015-03-12 | 2016-03-10 | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017019343A2 true BR112017019343A2 (pt) | 2018-05-02 |
Family
ID=56880599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017019343A BR112017019343A2 (pt) | 2015-03-12 | 2016-03-10 | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas |
Country Status (13)
Country | Link |
---|---|
US (1) | US9999655B2 (pt) |
EP (1) | EP3268022A4 (pt) |
JP (1) | JP2018512401A (pt) |
KR (1) | KR20170125090A (pt) |
CN (1) | CN107921082A (pt) |
AU (1) | AU2016229017A1 (pt) |
BR (1) | BR112017019343A2 (pt) |
CA (1) | CA2978941A1 (pt) |
HK (1) | HK1249433A1 (pt) |
MX (1) | MX2017011633A (pt) |
RU (1) | RU2017135072A (pt) |
SG (1) | SG11201707281QA (pt) |
WO (1) | WO2016145234A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018102827A1 (en) * | 2016-12-04 | 2018-06-07 | Expression Pathology, Inc. | Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy |
CN110662844A (zh) | 2017-05-22 | 2020-01-07 | 内盖夫生物技术国家研究所有限公司 | 用于肺癌的诊断的生物标志物 |
US10952799B2 (en) | 2017-05-31 | 2021-03-23 | Covidien Lp | Systems and methods for navigational bronchoscopy and selective drug delivery |
US20190134153A1 (en) * | 2017-06-12 | 2019-05-09 | Moerae Matrix, Inc. | Immunomodulatory effect of inhaled kinase inhibitor peptides in lung |
US20210253635A1 (en) * | 2018-06-12 | 2021-08-19 | Universite De Geneve | Peptidic protein kinase c inhibitors and uses thereof |
US11195062B2 (en) | 2018-11-15 | 2021-12-07 | Nantomics, Llc | Classification based on characterization analysis methods and systems |
CA3147575A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
CN113261532A (zh) * | 2020-02-17 | 2021-08-17 | 中山大学 | 一种肺癌动物模型的构建方法 |
EP4114411A4 (en) * | 2020-03-02 | 2024-04-24 | Washington University St Louis | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER |
CN116437962A (zh) * | 2020-11-18 | 2023-07-14 | 隆萨本德公司 | 包括血管生成抑制剂的可吸入干粉调配物 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
CA1224992A (en) | 1982-10-08 | 1987-08-04 | Robert E. Newell | Device for administering medicament to patients |
IL79550A (en) | 1985-07-30 | 1991-06-10 | Glaxo Group Ltd | Devices for administering medicaments to patients |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
KR100386337B1 (ko) | 1993-12-09 | 2004-03-24 | 토마스 제퍼슨 대학교 | 진핵세포에서부위-특이적돌연변이를위한화합물과그방법 |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
WO2001000654A2 (en) | 1999-06-29 | 2001-01-04 | Pharmaceutical Discovery Corporation | Purification and stabilization of peptide and proteins in pharmaceutical agents |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
ES2540853T3 (es) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Sales de dicetopiperazina para la administración de fármacos |
CA2575684A1 (en) | 2004-08-23 | 2006-03-02 | Mannkind Corporation | Pulmonary delivery of inhibitors of phosphodiesterase type 5 |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
DK2617431T3 (en) * | 2007-01-10 | 2017-07-10 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and applications therefor |
WO2009021137A2 (en) * | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
CA2741302C (en) | 2008-10-20 | 2017-02-28 | Moerae Matrix, Inc. | Mapkap kinase inhibitor polypeptide for treating or preventing adhesions |
EP2378875B1 (en) * | 2008-12-10 | 2018-05-30 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
WO2011017132A2 (en) | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US9890200B2 (en) * | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
WO2012142320A2 (en) * | 2011-04-12 | 2012-10-18 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
AU2013273242B2 (en) | 2012-06-06 | 2019-04-11 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
US20140072613A1 (en) | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
-
2016
- 2016-03-10 KR KR1020177028070A patent/KR20170125090A/ko unknown
- 2016-03-10 JP JP2017548089A patent/JP2018512401A/ja active Pending
- 2016-03-10 RU RU2017135072A patent/RU2017135072A/ru not_active Application Discontinuation
- 2016-03-10 WO PCT/US2016/021843 patent/WO2016145234A2/en active Application Filing
- 2016-03-10 SG SG11201707281QA patent/SG11201707281QA/en unknown
- 2016-03-10 CN CN201680022723.9A patent/CN107921082A/zh active Pending
- 2016-03-10 BR BR112017019343A patent/BR112017019343A2/pt not_active Application Discontinuation
- 2016-03-10 CA CA2978941A patent/CA2978941A1/en not_active Abandoned
- 2016-03-10 EP EP16762545.8A patent/EP3268022A4/en not_active Withdrawn
- 2016-03-10 MX MX2017011633A patent/MX2017011633A/es unknown
- 2016-03-10 AU AU2016229017A patent/AU2016229017A1/en not_active Abandoned
- 2016-03-10 US US15/066,976 patent/US9999655B2/en not_active Expired - Fee Related
-
2018
- 2018-07-13 HK HK18109079.5A patent/HK1249433A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017135072A3 (pt) | 2019-09-30 |
KR20170125090A (ko) | 2017-11-13 |
HK1249433A1 (zh) | 2018-11-02 |
SG11201707281QA (en) | 2017-10-30 |
WO2016145234A3 (en) | 2016-11-03 |
US20160263187A1 (en) | 2016-09-15 |
JP2018512401A (ja) | 2018-05-17 |
CN107921082A (zh) | 2018-04-17 |
CA2978941A1 (en) | 2016-09-15 |
US9999655B2 (en) | 2018-06-19 |
EP3268022A2 (en) | 2018-01-17 |
RU2017135072A (ru) | 2019-04-10 |
AU2016229017A1 (en) | 2017-09-28 |
WO2016145234A2 (en) | 2016-09-15 |
MX2017011633A (es) | 2017-11-02 |
EP3268022A4 (en) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
BR112019024674A2 (pt) | Inibidores covalentes da kras | |
BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
BR112017021869A2 (pt) | compostos quinazolina substituídos e métodos de uso dos mesmos | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112017008042A2 (pt) | métodos e composições para dosagem em terapia de célula adotiva | |
BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
BR112015027288A8 (pt) | uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit | |
BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
BR112013011184A2 (pt) | composições e métodos para tratamento de mielofibrose | |
BR112019005046A2 (pt) | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |